Recce Pharmaceuticals completes dosing for Phase I/II UTI/Urosepsis clinical trial

Recce Pharmaceuticals Limited (ASX: $RCE) has successfully completed dosing of 4 clinical subjects in its Phase I/II UTI/Urosepsis fast infusion I.V. study of RECCE® 327 at 3,000mg over 20 minutes. The data from this cohort will support preparations for a Phase II UTI/Urosepsis efficacy clinical trial. An Independent Safety Committee will review and evaluate the comprehensive data from the 4-subject cohort, with recruitment for the next cohort already underway.

Executive Commentary on Phase I/II UTI/Urosepsis clinical trial

Completing dosing for our latest cohort marks another milestone in our journey advancing R327 as a potential frontline treatment for UTI/Urosepsis. We are dedicated to delivering impactful solutions to combat infectious diseases and improve global health outcomes globally.

Summary of Phase I/II UTI/Urosepsis clinical trial completion

Recce Pharmaceuticals (ASX: $RCE) has successfully completed dosing for its Phase I/II UTI/Urosepsis clinical trial, evaluating RECCE® 327 at fast infusion rates. The data from this trial is expected to pave the way for a Phase II UTI/Urosepsis efficacy trial, potentially establishing R327 as a frontline treatment. The administration of antibiotics via rapid intravenous infusions is a proven safe and effective method of administration, impacting patient treatment, wait times, and nursing workloads globally. Recce Pharmaceuticals is dedicated to delivering impactful solutions to combat infectious diseases and improve global health outcomes globally. The company's anti-infective pipeline, including RECCE® 327, RECCE 435, and RECCE® 529, aims to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. RECCE® 327 has been awarded Qualified Infectious Disease Product designation by the FDA and has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline. The company's ambitions include developing synthetic anti-infectives to overcome the hypercellular mutation of bacteria and viruses, targeting synergistic, unmet medical needs.